Literature DB >> 10751788

Targeted Coronary Thrombolysis via "Pericardial" Administration of Lytic Agents?

.   

Abstract

Entities:  

Year:  1998        PMID： 10751788     DOI： 10.1023/A:1008870700908

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  22 in total

1.  Adventitia as a target for intravascular local drug delivery.

Authors:  T Y Huehns; P Gonschior; B Höfling
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

2.  Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study.

Authors:  L E Strandberg; T Kahan; P Lundin; J Svensson; L Erhardt
Journal:  Haemostasis       Date:  1996 Sep-Oct

3.  Intrapericardial administration of adenovirus for gene transfer.

Authors:  K G Lamping; C D Rios; J A Chun; H Ooboshi; B L Davidson; D D Heistad
Journal:  Am J Physiol       Date:  1997-01

4.  Vascular endothelial growth factor administration in chronic myocardial ischemia.

Authors:  K Harada; M Friedman; J J Lopez; S Y Wang; J Li; P V Prasad; J D Pearlman; E R Edelman; F W Sellke; M Simons
Journal:  Am J Physiol       Date:  1996-05

5.  Use of streptokinase to aid in drainage of postoperative pericardial effusion.

Authors:  J H Cross; J V De Giovanni; E D Silove
Journal:  Br Heart J       Date:  1989-09

6.  The protective effect of heparin in a dog model of rethrombosis following pharmacologic thrombolysis.

Authors:  S Voytik; S F Badylak; S Burke; R E Klabunde; J Henkin; A Simmons
Journal:  Thromb Haemost       Date:  1990-11-30       Impact factor: 5.249

7.  Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine.

Authors:  P Whittaker; R A Kloner; K Przyklenk
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

8.  Sotalol controlled-release systems for arrhythmias: in vitro characterization, in vivo drug disposition, and electrophysiologic effects.

Authors:  V Labhasetwar; T Underwood; M Gallagher; G Murphy; J Langberg; R J Levy
Journal:  J Pharm Sci       Date:  1994-02       Impact factor: 3.534

9.  Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.

Authors:  K Przyklenk; R A Kloner
Journal:  Cardiovasc Res       Date:  1993-06       Impact factor: 10.787

10.  Thrombolytic therapy of acute myocardial infarction alters collagen metabolism.

Authors:  N B Høst; S S Hansen; L T Jensen; D Husum; J D Nielsen
Journal:  Cardiology       Date:  1994       Impact factor: 1.869
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.